Skip to main content
. 2024 Jan 10;14:939. doi: 10.1038/s41598-024-51383-2

Figure 3.

Figure 3

(A) Significant difference was observed in the serum galectin-3 levels in surviving and deceased HD patients (p < 0.001). (B) Kaplan–Meier survival analysis for mortality in the two groups by serum galectin-3 level of 37.0 ng/mL. Patients with galectin-3 ≥ 37.0 ng/mL had significantly higher mortality rates than those with lower levels.